AR117510A1 - COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS - Google Patents

COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS

Info

Publication number
AR117510A1
AR117510A1 ARP190103859A ARP190103859A AR117510A1 AR 117510 A1 AR117510 A1 AR 117510A1 AR P190103859 A ARP190103859 A AR P190103859A AR P190103859 A ARP190103859 A AR P190103859A AR 117510 A1 AR117510 A1 AR 117510A1
Authority
AR
Argentina
Prior art keywords
probenecid
lactama
combinations
same
layer
Prior art date
Application number
ARP190103859A
Other languages
English (en)
Inventor
Aaron Cameron
Tom Loughman
Michael Dunne
Original Assignee
Iterum Therapeutics International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterum Therapeutics International Ltd filed Critical Iterum Therapeutics International Ltd
Publication of AR117510A1 publication Critical patent/AR117510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a comprimidos bicapa que comprenden una segunda capa que comprende un compuesto b-lactama o una sal farmacéuticamente aceptable del mismo; y una primera capa que comprende probenecid o una sal farmacéuticamente aceptable del mismo. La presente también se refiere a métodos para tratar o prevenir una enfermedad usando los comprimidos bicapa.
ARP190103859A 2019-02-13 2019-12-23 COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS AR117510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962804973P 2019-02-13 2019-02-13

Publications (1)

Publication Number Publication Date
AR117510A1 true AR117510A1 (es) 2021-08-11

Family

ID=69105866

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103859A AR117510A1 (es) 2019-02-13 2019-12-23 COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS

Country Status (13)

Country Link
US (3) US11478428B2 (es)
EP (1) EP3790535A1 (es)
JP (1) JP7295964B2 (es)
KR (1) KR102577614B1 (es)
CN (1) CN112739330A (es)
AR (1) AR117510A1 (es)
AU (1) AU2019429755B2 (es)
BR (1) BR112021015744A2 (es)
CA (1) CA3129337A1 (es)
EA (1) EA202192193A1 (es)
MX (1) MX2021009755A (es)
TW (1) TW202045143A (es)
WO (1) WO2020164788A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
KR102577614B1 (ko) 2019-02-13 2023-09-12 이테룸 테라퓨틱스 인터내셔널 리미티드 베타-락탐 화합물과 프로베네시드의 조합물, 및 이의 용도
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
UA59394C2 (uk) * 1998-03-27 2003-09-15 Каділа Фармацевтікелс (І.Ей) Лтд. Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти)
ES2220789T3 (es) 2000-10-30 2004-12-16 Lupin Limited Composicion de cefuroxima axetilo de liberacion lenta que se desintegra rapidamente.
AU2001227030A1 (en) * 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
WO2003043607A1 (en) * 2001-11-19 2003-05-30 Lupin Limited A pharmaceutical composition for controlled release of a beta-lactam antibiotic
CN1853724A (zh) * 2004-12-01 2006-11-01 吴晓辉 丙磺舒钠、钾与β－内酰胺类抗生素组成复方针剂及其用途
CN1813700A (zh) 2006-03-01 2006-08-09 吴晓辉 丙磺舒钠与青霉素类抗生素组成复方针剂
PE20080940A1 (es) 2006-06-28 2008-07-09 Pfizer Prod Inc Profarmacos de penem
US20080125408A1 (en) 2006-11-14 2008-05-29 Pfizer Inc Penem prodrug
ES2689107T3 (es) * 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
ES2647526T3 (es) * 2013-03-15 2017-12-22 Janssen Pharmaceutica Nv Combinación de canagliflozina y probenecid para el tratamiento de la hiperuricemia
TR201605632A1 (tr) * 2016-04-28 2017-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profen ve tramadolün yavaş salinimli kombi̇nasyonlari
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
KR102577614B1 (ko) 2019-02-13 2023-09-12 이테룸 테라퓨틱스 인터내셔널 리미티드 베타-락탐 화합물과 프로베네시드의 조합물, 및 이의 용도

Also Published As

Publication number Publication date
US20230138191A1 (en) 2023-05-04
JP7295964B2 (ja) 2023-06-21
EA202192193A1 (ru) 2021-11-09
US20210154176A1 (en) 2021-05-27
MX2021009755A (es) 2021-11-17
AU2019429755B2 (en) 2023-07-20
TW202045143A (zh) 2020-12-16
US11478428B2 (en) 2022-10-25
WO2020164788A1 (en) 2020-08-20
KR102577614B1 (ko) 2023-09-12
JP2022520788A (ja) 2022-04-01
AU2019429755A1 (en) 2021-08-26
BR112021015744A2 (pt) 2021-11-23
US20200253878A1 (en) 2020-08-13
CA3129337A1 (en) 2020-08-20
EP3790535A1 (en) 2021-03-17
KR20210131364A (ko) 2021-11-02
CN112739330A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
AR117510A1 (es) COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2020002530A1 (es) Ciano tienotriazolpirazinas y usos de las mismas.(divisional de solicitud 621-2018)
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
CL2020002496A1 (es) Moduladores calpaína y usos terapéuticos de los mismos
CL2019003258A1 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos.
DOP2023000251A (es) Compuestos oligoméricos que inhiben la expresión de hsd17b13
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
AR088497A1 (es) Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
AR115509A1 (es) COMBINACIONES DE COMPUESTOS DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS
CL2014003072A1 (es) Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro.
AR113817A1 (es) Compuestos útiles para inhibir a cdk7

Legal Events

Date Code Title Description
FB Suspension of granting procedure